2. Academic Validation
  3. Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254)

Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254)

  • Bioorg Med Chem. 2020 Jan 15;28(2):115227. doi: 10.1016/j.bmc.2019.115227.
Bin Yang 1,  Alexander W Hird 2,  Michael S Bodnarchuk 3,  Xiaolan Zheng 2,  Les Dakin 2,  Qibin Su 2,  Kevin Daly 2,  Robert Godin 4,  Maureen M Hattersley 4,  Patrick Brassil 5,  Sean Redmond 6,  Daniel John Russell 2,  James W Janetka 2
Affiliations

Affiliations

  • 1 Medicinal Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA 02451, USA. Electronic address: byang@kymeratx.com.
  • 2 Medicinal Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA 02451, USA.
  • 3 Medicinal Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Building 310, Cambridge Science Park, Milton Road, Cambridge, UK.
  • 4 Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA 02451, USA.
  • 5 Drug Metabolism and Pharmacokinetics, Oncology, IMED Biotech Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA 02451, USA.
  • 6 Oncology Safety, Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA 02451, USA.
PMID: 31862310 DOI: 10.1016/j.bmc.2019.115227
Abstract

Aberrant Hedgehog (Hh) pathway signaling is implicated in multiple Cancer types and targeting the Smoothened (Smo) receptor, a key protein of the Hh pathway, has proven effective in treating metastasized basal cell carcinoma. Our lead optimization effort focused on a series of heteroarylamides. We observed that a methyl substitution ortho to the heteroaryl groups on an aniline core significantly improved the potency of this series of compounds. These findings predated the availability of Smo crystal structure in 2013. Here we retrospectively applied quantum mechanics calculations to demonstrate the o-Me substitution favors the bioactive conformation by inducing a dihedral twist between the heteroaryl rings and the core aniline. The o-Me also makes favorable hydrophobic interactions with key residue side chains in the binding pocket. From this effort, two compounds (AZD8542 and AZD7254) showed excellent pharmacokinetics across multiple preclinical species and demonstrated in vivo activity in abrogating the Hh paracrine pathway as well as anti- tumor effects.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z